{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:49Z","timestamp":1790384329105,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00996-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:32:14Z","timestamp":1783611134000},"page":"2377-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining and Measuring Cognitive Decline and Clinical Relevance"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-6240","authenticated-orcid":false,"given":"Carolin","family":"Kurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Wyman-Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola T.","family":"Lautenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"996_CR1","doi-asserted-by":"publisher","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20:3708\u2013821. https:\/\/doi.org\/10.1002\/alz.13809.","DOI":"10.1002\/alz.13809"},{"key":"996_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1.","journal-title":"Lancet Neurol"},{"key":"996_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"996_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s43587-024-00675-3","volume":"4","author":"O Hansson","year":"2024","unstructured":"Hansson O, Jack CR Jr. A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer\u2019s disease. Nat Aging. 2024;4:1029\u201331. https:\/\/doi.org\/10.1038\/s43587-024-00675-3.","journal-title":"Nat Aging"},{"key":"996_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"996_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"996_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","volume":"10","author":"PS Sachdev","year":"2014","unstructured":"Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol. 2014;10:634\u201342. https:\/\/doi.org\/10.1038\/nrneurol.2014.181.","journal-title":"Nat Rev Neurol"},{"key":"996_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1212\/WNL.0000000000206891","volume":"100","author":"EA Largent","year":"2023","unstructured":"Largent EA, Grill JD, O\u2019Brien K, et al. Testing for Alzheimer disease biomarkers and disclosing results across the disease continuum. Neurology. 2023;100:1010\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000206891.","journal-title":"Neurology"},{"key":"996_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia J, Ning Y, Chen M, et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N Engl J Med. 2024;390:712\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2310168.","journal-title":"N Engl J Med"},{"key":"996_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3233\/JAD-215077","volume":"84","author":"JE Galvin","year":"2021","unstructured":"Galvin JE, Kleiman MJ, Chrisphonte S, et al. The resilience index: a quantifiable measure of brain health and risk of cognitive impairment and dementia. J Alzheimers Dis. 2021;84:1729\u201346. https:\/\/doi.org\/10.3233\/JAD-215077.","journal-title":"J Alzheimers Dis"},{"key":"996_CR11","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197\u2013204. https:\/\/doi.org\/10.1212\/01.wnl.0000271090.28148.24.","journal-title":"Neurology"},{"key":"996_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209753","volume":"103","author":"A Bieger","year":"2024","unstructured":"Bieger A, Brum WS, Borelli WV, et al. Influence of different diagnostic criteria on Alzheimer disease clinical research. Neurology. 2024;103:e209753. https:\/\/doi.org\/10.1212\/WNL.0000000000209753.","journal-title":"Neurology"},{"key":"996_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332:1245\u201357. https:\/\/doi.org\/10.1001\/jama.2024.13855.","journal-title":"JAMA"},{"key":"996_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002.","journal-title":"Alzheimers Dement"},{"key":"996_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/0004867413514493","volume":"48","author":"JC Looi","year":"2014","unstructured":"Looi JC, Velakoulis D. Major and minor neurocognitive disorders in DSM-5: the difference between the map and the terrain. Aust NZ J Psychiatry. 2014;48:284\u20136. https:\/\/doi.org\/10.1177\/0004867413514493.","journal-title":"Aust NZ J Psychiatry"},{"key":"996_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaneurol.2023.3664","volume":"80","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Weintraub S, Sabbagh M, et al. A new framework for dementia nomenclature. JAMA Neurol. 2023;80:1364\u201370. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3664.","journal-title":"JAMA Neurol"},{"key":"996_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"996_CR18","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1002\/alz.12945","volume":"19","author":"TS Ellison","year":"2023","unstructured":"Ellison TS, Cappa SF, Garrett D, et al. Outcome measures for Alzheimer\u2019s disease: a global inter-societal Delphi consensus. Alzheimers Dement. 2023;19:2707\u201329. https:\/\/doi.org\/10.1002\/alz.12945.","journal-title":"Alzheimers Dement"},{"key":"996_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14283\/jpad.2015.82","volume":"2","author":"AM Wessels","year":"2015","unstructured":"Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s disease rating scale (iADRS). J Prev Alzheimers Dis. 2015;2:227\u201341. https:\/\/doi.org\/10.14283\/jpad.2015.82.","journal-title":"J Prev Alzheimers Dis"},{"key":"996_CR20","unstructured":"(FDA). OoNitCfDEaRicwtCfBEaRatFaDA. Early Alzheimer\u2019s disease: developing drugs for treatment guidance for industry. https:\/\/www.fda.gov\/media\/110903\/download. 2024."},{"key":"996_CR21","unstructured":"(CHMP) EMA-CfMPfHU. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. 2018;CPMP\/EWP\/553\/95 Rev. 1."},{"key":"996_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x.","journal-title":"J Intern Med"},{"key":"996_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1071\/HC20115","volume":"13","author":"Y Maki","year":"2021","unstructured":"Maki Y. Reconsidering the overdiagnosis of mild cognitive impairment for dementia prevention among adults aged >\/=80 years. J Prim Health Care. 2021;13:112\u20135. https:\/\/doi.org\/10.1071\/HC20115.","journal-title":"J Prim Health Care"},{"key":"996_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jalz.2014.03.005","volume":"11","author":"EC Edmonds","year":"2015","unstructured":"Edmonds EC, Delano-Wood L, Clark LR, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement. 2015;11:415\u201324. https:\/\/doi.org\/10.1016\/j.jalz.2014.03.005.","journal-title":"Alzheimers Dement"},{"key":"996_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jalz.2014.07.158","volume":"10","author":"PJ Snyder","year":"2014","unstructured":"Snyder PJ, Kahle-Wrobleski K, Brannan S, et al. Assessing cognition and function in Alzheimer\u2019s disease clinical trials: do we have the right tools? Alzheimers Dement. 2014;10:853\u201360. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.158.","journal-title":"Alzheimers Dement"},{"key":"996_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1037\/0894-4105.22.4.531","volume":"22","author":"ST Farias","year":"2008","unstructured":"Farias ST, Mungas D, Reed BR, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531\u201344. https:\/\/doi.org\/10.1037\/0894-4105.22.4.531.","journal-title":"Neuropsychology"},{"key":"996_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jama.2020.0435","volume":"323","author":"DK Owens","year":"2020","unstructured":"Force USPST, Owens DK, Davidson KW, et al. Screening for cognitive impairment in older adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323:757\u201363. https:\/\/doi.org\/10.1001\/jama.2020.0435.","journal-title":"JAMA"},{"key":"996_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.22258","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2020;323:764\u201385. https:\/\/doi.org\/10.1001\/jama.2019.22258.","journal-title":"JAMA"},{"key":"996_CR29","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1017\/S1041610214001082","volume":"26","author":"JE Yokomizo","year":"2014","unstructured":"Yokomizo JE, Simon SS, Bottino CM. Cognitive screening for dementia in primary care: a systematic review. Int Psychogeriatr. 2014;26:1783\u2013804. https:\/\/doi.org\/10.1017\/S1041610214001082.","journal-title":"Int Psychogeriatr"},{"key":"996_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","volume":"42","author":"MW Bondi","year":"2014","unstructured":"Bondi MW, Edmonds EC, Jak AJ, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis. 2014;42:275\u201389. https:\/\/doi.org\/10.3233\/JAD-140276.","journal-title":"J Alzheimers Dis"},{"key":"996_CR31","unstructured":"Policies OEOoHSa. Germany: Country Health Profile 2023, State of Health in the EU. https:\/\/eurohealthobservatory.who.int\/publications\/m\/germany-country-health-profile-2023. 2023."},{"key":"996_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0.","journal-title":"Lancet"},{"key":"996_CR33","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/ATVBAHA.119.311908","volume":"39","author":"FJ Wolters","year":"2019","unstructured":"Wolters FJ, Ikram MA. Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol. 2019;39:1542\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.119.311908.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"996_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100476","volume":"13","author":"A Rosenberg","year":"2026","unstructured":"Rosenberg A, Solomon A, Bonnard A, et al. Preparing for the implementation of anti-amyloid therapies in Europe: assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. J Prev Alzheimers Dis. 2026;13:100476. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100476.","journal-title":"J Prev Alzheimers Dis"},{"key":"996_CR35","unstructured":"Neurologie DGfPuPDGf. S3-Leitlinie Demenzen\u2014living guideline. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-013. 2025."},{"key":"996_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JAD-220755","volume":"90","author":"MS Joshi","year":"2022","unstructured":"Joshi MS, Galvin JE. Cognitive resilience in brain health and dementia research. J Alzheimers Dis. 2022;90:461\u201373. https:\/\/doi.org\/10.3233\/JAD-220755.","journal-title":"J Alzheimers Dis"},{"key":"996_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2026.100831","author":"K Giorgio","year":"2026","unstructured":"Giorgio K, Stephen JJ, Mansolf M, et al. Risk factors for early-onset and late-onset dementia: a prospective cohort study. Lancet Healthy Longev. 2026. https:\/\/doi.org\/10.1016\/j.lanhl.2026.100831.","journal-title":"Lancet Healthy Longev"},{"key":"996_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/svn-2025-004048","volume":"10","author":"S Ng","year":"2025","unstructured":"Ng S, Hornblass A, Habibi P, et al. Updates on vascular dementia. Stroke Vasc Neurol. 2025;10:542\u201350. https:\/\/doi.org\/10.1136\/svn-2025-004048.","journal-title":"Stroke Vasc Neurol"},{"key":"996_CR39","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1038\/s41591-024-03012-8","volume":"30","author":"J Verghese","year":"2024","unstructured":"Verghese J, Chalmer R, Stimmel M, et al. Non-literacy biased, culturally fair cognitive detection tool in primary care patients with cognitive concerns: a randomized controlled trial. Nat Med. 2024;30:2356\u201361. https:\/\/doi.org\/10.1038\/s41591-024-03012-8.","journal-title":"Nat Med"},{"key":"996_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3233\/JAD-150692","volume":"49","author":"B Dubois","year":"2016","unstructured":"Dubois B, Padovani A, Scheltens P, et al. Timely diagnosis for Alzheimer\u2019s disease: a literature review on benefits and challenges. J Alzheimers Dis. 2016;49:617\u201331. https:\/\/doi.org\/10.3233\/JAD-150692.","journal-title":"J Alzheimers Dis"},{"key":"996_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"996_CR42","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/wnl.39.9.1159","volume":"39","author":"JC Morris","year":"1989","unstructured":"Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology. 1989;39:1159\u201365. https:\/\/doi.org\/10.1212\/wnl.39.9.1159.","journal-title":"Neurology"},{"key":"996_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2021.07.034","volume":"90","author":"R Lillig","year":"2021","unstructured":"Lillig R, Ophey A, Schulz JB, et al. A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic \u201cCERAD-Plus\u201d tests enhances cognitive diagnosis in patients with Parkinson\u2019s disease: evidence from the LANDSCAPE study. Parkinsonism Relat Disord. 2021;90:90\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.07.034.","journal-title":"Parkinsonism Relat Disord"},{"key":"996_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00299-w","volume":"11","author":"F Rodriguez-Porcel","year":"2022","unstructured":"Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, et al. Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener. 2022;11:24. https:\/\/doi.org\/10.1186\/s40035-022-00299-w.","journal-title":"Transl Neurodegener"},{"key":"996_CR45","doi-asserted-by":"publisher","first-page":"1382593","DOI":"10.3389\/fnagi.2024.1382593","volume":"16","author":"JLP Fieldhouse","year":"2024","unstructured":"Fieldhouse JLP, van Paassen DN, van Engelen ME, et al. The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials. Front Aging Neurosci. 2024;16:1382593. https:\/\/doi.org\/10.3389\/fnagi.2024.1382593.","journal-title":"Front Aging Neurosci"},{"key":"996_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70723","volume":"21","author":"MJ Kleiman","year":"2025","unstructured":"Kleiman MJ, Gibbs G, Joshi MS, et al. The brain health index: integrating vulnerability, resilience, and cognitive function into a unified measure of cognitive health and risk of neurodegenerative disease. Alzheimers Dement. 2025;21:e70723. https:\/\/doi.org\/10.1002\/alz.70723.","journal-title":"Alzheimers Dement"},{"key":"996_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179\u201386.","journal-title":"Gerontologist"},{"key":"996_CR48","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"key":"996_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JAD-132027","volume":"41","author":"L Rami","year":"2014","unstructured":"Rami L, Mollica MA, Garcia-Sanchez C, et al. The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study. J Alzheimers Dis. 2014;41:453\u201366. https:\/\/doi.org\/10.3233\/JAD-132027.","journal-title":"J Alzheimers Dis"},{"key":"996_CR50","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1017\/s0033291700005742","volume":"19","author":"AF Jorm","year":"1989","unstructured":"Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19:1015\u201322. https:\/\/doi.org\/10.1017\/s0033291700005742.","journal-title":"Psychol Med"},{"key":"996_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-023-00631-6","volume":"18","author":"Z Ismail","year":"2023","unstructured":"Ismail Z, Leon R, Creese B, et al. Optimizing detection of Alzheimer\u2019s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Mol Neurodegener. 2023;18:50. https:\/\/doi.org\/10.1186\/s13024-023-00631-6.","journal-title":"Mol Neurodegener"},{"key":"996_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.acn.2004.11.004","volume":"20","author":"TN Tombaugh","year":"2005","unstructured":"Tombaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol. 2005;20:485\u2013503. https:\/\/doi.org\/10.1016\/j.acn.2004.11.004.","journal-title":"Arch Clin Neuropsychol"},{"key":"996_CR53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/mds.27335","volume":"33","author":"KA Wyman-Chick","year":"2018","unstructured":"Wyman-Chick KA, Martin PK, Weintraub D, et al. Selection of normative group affects rates of mild cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2018;33:839\u201343. https:\/\/doi.org\/10.1002\/mds.27335.","journal-title":"Mov Disord"},{"key":"996_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12438","volume":"15","author":"BE Gavett","year":"2023","unstructured":"Gavett BE, Ilango SD, Koscik R, et al. Harmonization of cognitive screening tools for dementia across diverse samples: a simulation study. Alzheimers Dement (Amst). 2023;15:e12438. https:\/\/doi.org\/10.1002\/dad2.12438.","journal-title":"Alzheimers Dement (Amst)"},{"key":"996_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12453","volume":"15","author":"J Giorgio","year":"2023","unstructured":"Giorgio J, Tanna A, Malpetti M, et al. A robust harmonization approach for cognitive data from multiple aging and dementia cohorts. Alzheimers Dement (Amst). 2023;15:e12453. https:\/\/doi.org\/10.1002\/dad2.12453.","journal-title":"Alzheimers Dement (Amst)"},{"key":"996_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-023-00443-2","volume":"12","author":"DB DiBenedetti","year":"2023","unstructured":"DiBenedetti DB, Menne H, Paulsen R, et al. Technical review of clinical outcomes assessments across the continuum of Alzheimer\u2019s disease. Neurol Ther. 2023;12:571\u201395. https:\/\/doi.org\/10.1007\/s40120-023-00443-2.","journal-title":"Neurol Ther"},{"key":"996_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70138","volume":"11","author":"JL Hamilton","year":"2025","unstructured":"Hamilton JL, Fuller RLM, Modi N, et al. Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions. Alzheimers Dement (NY). 2025;11:e70138. https:\/\/doi.org\/10.1002\/trc2.70138.","journal-title":"Alzheimers Dement (NY)"},{"key":"996_CR58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/arclin\/acr120","volume":"27","author":"K Duff","year":"2012","unstructured":"Duff K. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol. 2012;27:248\u201361. https:\/\/doi.org\/10.1093\/arclin\/acr120.","journal-title":"Arch Clin Neuropsychol"},{"key":"996_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-12056-y","volume":"24","author":"D Gebhard","year":"2024","unstructured":"Gebhard D, Lang L, Maier MJ, et al. Social interaction of people living with dementia in residential long-term care: an ecological momentary assessment study. BMC Health Serv Res. 2024;24:1640. https:\/\/doi.org\/10.1186\/s12913-024-12056-y.","journal-title":"BMC Health Serv Res"},{"key":"996_CR60","unstructured":"Wilson JMG. JG. Principles and practice of screening for disease. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/762f0d2f-4225-46df-b060-c39b37b9d76d\/content. 1968."},{"key":"996_CR61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/blt.07.050112","volume":"86","author":"A Andermann","year":"2008","unstructured":"Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86:317\u20139. https:\/\/doi.org\/10.2471\/blt.07.050112.","journal-title":"Bull World Health Organ"},{"key":"996_CR62","doi-asserted-by":"publisher","DOI":"10.1177\/08919887261429550","author":"P Tegethoff","year":"2026","unstructured":"Tegethoff P, Taute M, Rutt S, et al. Subjective cognitive complaints and objective cognitive performance across diagnostic groups in memory clinic patients: a cross-sectional comparison of the SCD-Q and CFQ questionnaires. J Geriatr Psychiatry Neurol. 2026. https:\/\/doi.org\/10.1177\/08919887261429550.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"996_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2019-000767","author":"H Donovan","year":"2020","unstructured":"Donovan H, Ellis E, Cole L, et al. Reducing time to complete neuropsychological assessments within a memory assessment service and evaluating the wider impact. BMJ Open Qual. 2020. https:\/\/doi.org\/10.1136\/bmjoq-2019-000767.","journal-title":"BMJ Open Qual"},{"key":"996_CR64","doi-asserted-by":"publisher","DOI":"10.53841\/bpsneur.2025.1.19-20.42","author":"L King","year":"2025","unstructured":"King L, Reilly J, Isherwood A, Watkins C, Staddon T, Das L. Reducing young-onset dementia (YoD) assessment waiting times in North Staffordshire Neuropsychology (NSN). Neuropsychologist. 2025. https:\/\/doi.org\/10.53841\/bpsneur.2025.1.19-20.42.","journal-title":"Neuropsychologist"},{"key":"996_CR65","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210217","volume":"104","author":"CC Lin","year":"2025","unstructured":"Lin CC, Muthukumar L, Reynolds EL, et al. Wait time to see a neurologist after referral among Medicare participants. Neurology. 2025;104:e210217. https:\/\/doi.org\/10.1212\/WNL.0000000000210217.","journal-title":"Neurology"},{"key":"996_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70058","volume":"11","author":"LE Stoeckel","year":"2025","unstructured":"Stoeckel LE, Fazio EM, Hardy KK, et al. Clinically meaningful outcomes in Alzheimer\u2019s disease and Alzheimer\u2019s disease related dementias trials. Alzheimers Dement (NY). 2025;11:e70058. https:\/\/doi.org\/10.1002\/trc2.70058.","journal-title":"Alzheimers Dement (NY)"},{"key":"996_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/2047-9158-3-12","volume":"3","author":"JB Miller","year":"2014","unstructured":"Miller JB, Banks SJ, L\u00e9ger GC, et al. Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. Transl Neurodegener. 2014;3:12. https:\/\/doi.org\/10.1186\/2047-9158-3-12.","journal-title":"Transl Neurodegener"},{"key":"996_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000103865","volume":"24","author":"R Ylikoski","year":"2007","unstructured":"Ylikoski R, Jokinen H, Andersen P, et al. Comparison of the Alzheimer\u2019s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. Dement Geriatr Cogn Disord. 2007;24:73\u201381. https:\/\/doi.org\/10.1159\/000103865.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"996_CR69","doi-asserted-by":"publisher","DOI":"10.17863\/CAM.129327","author":"E Matar","year":"2026","unstructured":"Matar E, White S, Taylor J-P, Thomas A, McKeith I, Kane J, et al. The utility of a composite endpoint for tracking disease progression in Lewy body dementia. Alzheimer\u2019s Dement Transl Res Clin Interv. 2026. https:\/\/doi.org\/10.17863\/CAM.129327.","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv."},{"key":"996_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40120-024-00676-9","volume":"14","author":"J Campbell","year":"2025","unstructured":"Campbell J, Lavoie L, Farraia M, et al. Quality of life in mild cognitive impairment and mild dementia associated with Alzheimer\u2019s disease: a systematic review. Neurol Ther. 2025;14:7\u201326. https:\/\/doi.org\/10.1007\/s40120-024-00676-9.","journal-title":"Neurol Ther"},{"key":"996_CR71","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.MS18002BR1C","volume":"80","author":"D Goldfarb","year":"2019","unstructured":"Goldfarb D, Sheard S, Shaughnessy L, et al. Disclosure of Alzheimer\u2019s disease and dementia: patient- and care partner-centric decision-making and communication. J Clin Psychiatry. 2019;80:20190319. https:\/\/doi.org\/10.4088\/JCP.MS18002BR1C.","journal-title":"J Clin Psychiatry"},{"key":"996_CR72","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1212\/WNL.0000000000207199","volume":"100","author":"EA McCusker","year":"2023","unstructured":"McCusker EA, Loy CT. Scientific, ethical, and practical considerations for the testing and disclosure of Alzheimer disease biomarkers. Neurology. 2023;100:993\u20134. https:\/\/doi.org\/10.1212\/WNL.0000000000207199.","journal-title":"Neurology"},{"key":"996_CR73","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389:1096\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa2305032.","journal-title":"N Engl J Med"},{"key":"996_CR74","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"996_CR75","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1017\/S1041610213002251","volume":"26","author":"K Dean","year":"2014","unstructured":"Dean K, Jenkinson C, Wilcock G, et al. The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment. Int Psychogeriatr. 2014;26:487\u201397. https:\/\/doi.org\/10.1017\/S1041610213002251.","journal-title":"Int Psychogeriatr"},{"key":"996_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70090","volume":"11","author":"R Perneczky","year":"2025","unstructured":"Perneczky R, Froelich L. Clinically meaningful benefit and real-world evidence in Alzheimer\u2019s disease research and care. Alzheimers Dement (NY). 2025;11:e70090. https:\/\/doi.org\/10.1002\/trc2.70090.","journal-title":"Alzheimers Dement (NY)"},{"key":"996_CR77","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352. https:\/\/doi.org\/10.1016\/j.jalz.2014.01.001.","journal-title":"Alzheimers Dement"},{"key":"996_CR78","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/gps.5268","volume":"35","author":"MY Ivanova","year":"2020","unstructured":"Ivanova MY, Achenbach TM, Rescorla LA, et al. The generalizability of older adult self-report (OASR) syndromes of psychopathology across 20 societies. Int J Geriatr Psychiatry. 2020;35:525\u201336. https:\/\/doi.org\/10.1002\/gps.5268.","journal-title":"Int J Geriatr Psychiatry"},{"key":"996_CR79","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/13854046.2021.1981456","volume":"36","author":"S Franzen","year":"2022","unstructured":"Franzen S, European Consortium on Cross-Cultural N, Watermeyer TJ, et al. Cross-cultural neuropsychological assessment in Europe: position statement of the European Consortium on Cross-Cultural Neuropsychology (ECCroN). Clin Neuropsychol. 2022;36:546\u201357. https:\/\/doi.org\/10.1080\/13854046.2021.1981456.","journal-title":"Clin Neuropsychol"},{"key":"996_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.1043721","volume":"13","author":"A Delgado-Alvarez","year":"2022","unstructured":"Delgado-Alvarez A, Delgado-Alonso C, Goudsmit M, et al. Validation of the cross-cultural dementia screening test in Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Psychol. 2022;13:1043721. https:\/\/doi.org\/10.3389\/fpsyg.2022.1043721.","journal-title":"Front Psychol"},{"key":"996_CR81","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1017\/S1041610220001532","volume":"34","author":"LA Rescorla","year":"2022","unstructured":"Rescorla LA, Ivanova MY, Achenbach TM, et al. Older adult psychopathology: international comparisons of self-reports, collateral reports, and cross-informant agreement. Int Psychogeriatr. 2022;34:467\u201378. https:\/\/doi.org\/10.1017\/S1041610220001532.","journal-title":"Int Psychogeriatr"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00996-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:23Z","timestamp":1790381003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00996-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00996-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kate Wyman serves as the Lead Principal Investigator of the Lewy Body Dementia Association\u2019s Research Center of Excellence at Struthers Parkinson\u2019s Center. She is a member of the Michael J Fox Foundation\u2019s PD\/DLB Cognition Measures Task Force (we are working on summarizing and optimizing clinical trial endpoints). Carolin Kurz has received speaker honoraria and consultancy fees from Roche Diagnostics (Penzberg, Germany). Nicola Theresa Lautenschlager and James Galvin report no conflicts of interest. Carolin Kurz is an Editorial Board member of Neurology and Therapy. Carolin Kurz was not involved in the\u00a0selection\u00a0of peer reviewers for the manuscript nor any of the\u00a0subsequent\u00a0editorial decisions.\u00a0Paul Newhouse is an Editorial Board member of Neurology and Therapy. Paul Newhouse was not involved in the\u00a0selection\u00a0of peer reviewers for the manuscript nor any of the\u00a0subsequent\u00a0editorial decisions.\u00a0Marwan Sabbagh is an Editor-in-Chief of\n                      Neurology and Therapy\n                      . Marwan Sabbagh was not involved in the\u00a0selection\u00a0of peer reviewers for the manuscript nor any of the\u00a0subsequent\u00a0editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article and does not involve any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}